Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update
November 14, 2017 17:40 ET
|
Proteostasis Therapeutics, Inc.
Preliminary Data from PTI-428 + Orkambi 28 Day Clinical Study on Track for Q4 2017 Initial Data from PTI-801 + Orkambi 14 Day Clinical Trial Anticipated in Q4 2017 Initial Data from PTI-808 SAD and...
Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs
October 31, 2017 16:05 ET
|
Proteostasis Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects
July 31, 2017 16:16 ET
|
Proteostasis Therapeutics, Inc
PTI-801 Moving to 14 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-428 Continues to Enroll 28 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-808 Investigational New Drug...
Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer
July 31, 2017 16:15 ET
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis
June 29, 2017 07:00 ET
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator
June 23, 2017 07:00 ET
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs
June 07, 2017 07:00 ET
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
March 30, 2017 16:30 ET
|
Proteostasis Therapeutics, Inc
PTI-801 Receives FDA Fast Track Designation; Phase 1 Study Underway IND Submission for PTI-808 Planned for 2Q17 Phase 1 Study of PTI-428 Updated and Ongoing; Results Expected 2Q17 CAMBRIDGE, Mass.,...
Proteostasis Therapeutics Reports Third Quarter 2016 Financial Results
November 10, 2016 07:00 ET
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American Cystic Fibrosis Conference
October 26, 2016 16:05 ET
|
Proteostasis Therapeutics, Inc
CAMBRIDGE, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...